These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 1150540)

  • 1. Phenopicolinic acid, a new microbial product inhibiting dopamine beta-hydroxylase.
    Nakamura T; Yasuda H; Obayashi A; Tanabe O; Matsumura S
    J Antibiot (Tokyo); 1975 Jun; 28(6):477-8. PubMed ID: 1150540
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacological action of FD-008, a new dopamine-beta-hydroxylase inhibitor.
    Ishii Y; Natsugoe K; Umezawa H
    Arzneimittelforschung; 1975 Feb; 25(2):213-5. PubMed ID: 1173034
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Behavioral effects of a new dopamine-beta-hydroxylase inhibitor (fusaric acid) in man.
    Goodwin FK; Sack RL
    J Psychiatr Res; 1974; 11():211-7. PubMed ID: 4618285
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of 5-(n-butyl)-picolinamide (SCH 10595), a dopamine-beta-hydroxylase inhibitor, on serotonin and catecholamine metabolites in brain.
    Korduba CA; Veals J; Symchowicz S
    J Pharmacol Exp Ther; 1974 Sep; 190(3):459-65. PubMed ID: 4413186
    [No Abstract]   [Full Text] [Related]  

  • 5. Selective suppression of rapid eye movement sleep (REM) by fusaric acid, an inhibitor of dopamine- -oxidase.
    Sato T; Tanaka R
    Experientia; 1973 Feb; 29(2):177-8. PubMed ID: 4348192
    [No Abstract]   [Full Text] [Related]  

  • 6. Inhibition of human serum dopamine -hydroxylase after the oral administration of fusaric acid.
    Nagatsu T; Kato T; Kuzuya H; Okada T; Umezawa H; Takeuchi T
    Experientia; 1972 Jul; 28(7):779-80. PubMed ID: 4658852
    [No Abstract]   [Full Text] [Related]  

  • 7. Influence of fusaric acid on urinary excretion of catecholamines: a clinical study with particular emphasis on the characteristics of its time-course change.
    Ozawa N
    Jpn Circ J; 1972 Nov; 36(11):1205-21. PubMed ID: 4678992
    [No Abstract]   [Full Text] [Related]  

  • 8. Letter: Fusaric acid derivatives: the effect on dopamine beta-hydroxylase.
    Umezawa H; Takeuchi T; Miyano K; Koshigoe K; Hamano H
    J Antibiot (Tokyo); 1973 Mar; 26(3):189. PubMed ID: 4205877
    [No Abstract]   [Full Text] [Related]  

  • 9. Selective inhibition of dopamine-beta-hydroxylase in the peripheral tissues by 5-dimethyldithiocarbamylpicolinic acid; its effect on stress-induced ulcer, ethanol-induced sleep and blood pressure.
    Hidaka H; Hara F; Harada N; Hashizume Y; Yano M
    J Pharmacol Exp Ther; 1974 Dec; 191(3):384-92. PubMed ID: 4473535
    [No Abstract]   [Full Text] [Related]  

  • 10. Proceedings: In vivo inhibition of dopamine beta-hydroxylase and blood pressure.
    Hidaka H; Hara F; Harada N; Asano M
    Jpn J Pharmacol; 1974; 24(0):s:25. PubMed ID: 4545737
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of a dopamine beta-hydroxylase inhibitor on tissue catecholamine levels in spontaneously hypertensive rats subjected to immobilization-cold stress.
    Ishi Y; Homma M; Yoshikawa A
    Neuropharmacology; 1975 Feb; 14(2):155-7. PubMed ID: 1153081
    [No Abstract]   [Full Text] [Related]  

  • 12. Blood pressure decreased by halobutylpicolinic acid, an inhibitor of dopamine beta-hydroxylase.
    Hidaka H; Takeya K
    Nature; 1972 Oct; 239(5371):334-5. PubMed ID: 12635227
    [No Abstract]   [Full Text] [Related]  

  • 13. Evidence for a peripheral effect of fusaric acid, a dopamine beta-hydroxylase inhibitor, on serotonin metabolism.
    Bonnay MM; Guerinot F; Bohuon CJ
    Biochem Pharmacol; 1974 Oct; 23(19):2770-3. PubMed ID: 4419680
    [No Abstract]   [Full Text] [Related]  

  • 14. SCH 10595, an effective dopamine- -hydroxylase inhibitor and a hypotensive agent.
    Korduba CA; Veals J; Wohl A; Symchowicz S; Tabachnick II
    J Pharmacol Exp Ther; 1973 Mar; 184(3):671-7. PubMed ID: 4687230
    [No Abstract]   [Full Text] [Related]  

  • 15. Failure of peripheral dopamine beta-hydroxylase inhibitor to affect discriminated Sidman avoidance learning in rats under long-term training.
    Tamaki Y
    Psychol Rep; 1977 Jun; 40(3 Pt 2):936-8. PubMed ID: 866531
    [No Abstract]   [Full Text] [Related]  

  • 16. Preventive effect of fusaric acid, a dopamine beta-hydroxylase inhibitor, on the gastric ulceration induced by water-immersion stress in rats.
    Osumi Y; Takaori S; Fujiwara M
    Jpn J Pharmacol; 1973 Dec; 23(6):904-6. PubMed ID: 4544702
    [No Abstract]   [Full Text] [Related]  

  • 17. The effect of fusaric acid, inhibitor of dopamine -hydroxylase, on reaction to alcohol in chronic alcoholics: clinical findings.
    Ogata M; Sanada H; Teraoka M
    Folia Psychiatr Neurol Jpn; 1972 Jan; 26(1):1-5. PubMed ID: 5068469
    [No Abstract]   [Full Text] [Related]  

  • 18. Behavioral depression in Sidman avoidance learning induced by dopamine beta-hydroxylase inhibitors.
    Tamaki Y; Hidaka H
    Psychol Rep; 1976 Apr; 38(2):437-8. PubMed ID: 1265176
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of fusaric acid (a dopamine beta-hydroxylase inhibitor) on phaeochromocytoma.
    Nagasaka A; Hara I; Imai Y; Uchikawa T; Yamauchi K; Suzuki S; Takatsuki K; Tomita A; Niinomi M; Nakagawa H
    Clin Endocrinol (Oxf); 1985 Apr; 22(4):437-44. PubMed ID: 3987067
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analogues of fusaric (5-butylpicolinic) acid as potent inhibitors of dopamine -hydroxylase.
    Hidaka H; Asano T; Takemoto N
    Mol Pharmacol; 1973 Mar; 9(2):172-7. PubMed ID: 4197141
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.